{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:21:11Z","timestamp":1791991271749,"version":"4.4.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011684","name":"Crohn\u2019s and Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) is a chronic autoimmune disease in which inflammation can progress to complications of stricturing and\/or penetrating disease. Real-world data on burden of complicated CD phenotypes are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed cross-sectional data from the SPARC IBD (Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease) registry from 2016 to 2020. Four mutually exclusive phenotype cohorts were created: inflammatory CD (CD-I), complicated CD (stricturing CD, penetrating CD, and stricturing and penetrating CD [CD-SP]). Statistical analyses were performed using CD-I as the reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1557 patients were identified: CD-I (n\u2005=\u2005674, 43.3%), stricturing CD (n\u2005=\u2005457, 29.4%), penetrating CD (n\u2005=\u2005166, 10.7%), and CD-SP (n\u2005=\u2005260, 16.7%). Patients with complicated phenotypes reported significantly greater use of tumor necrosis factor inhibitors (84.2%-86.7% vs 66.0%; P\u2005&amp;lt;\u2005.001) and corticosteroids (75.3%-82.7% vs 68.0%; P\u2005&amp;lt;\u2005.001). Patients with CD-SP reported significantly more aphthous ulcer (15.4% vs 10.5%; P\u2005&amp;lt;\u2005.05), erythema nodosum (6.5% vs 3.6%; P\u2005&amp;lt;\u2005.05), inflammatory bowel disease-related arthropathy (25.8% vs 17.2%; P\u2005&amp;lt;\u2005.01), liquid stools (24.2% vs 9.3%; P\u2005&amp;lt;\u2005.001), nocturnal fecal incontinence (10.8% vs 2.5%; P\u2005&amp;lt;\u2005.001), and CD-related surgery (77.7% vs 12.2%; P\u2005&amp;lt;\u2005.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with complicated CD phenotypes reported higher rates of active CD-related luminal and extraintestinal manifestations, and underwent more surgeries, despite being more likely to have received biologics than those with CD-I. The potential for early recognition and management of CD-I to prevent progression to complicated phenotypes should be explored in longitudinal studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izac162","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T08:40:28Z","timestamp":1658824828000},"page":"914-922","source":"Crossref","is-referenced-by-count":26,"title":["Patients With Stricturing or Penetrating Crohn\u2019s Disease Phenotypes Report High Disease Burden and Treatment Needs"],"prefix":"10.1093","volume":"29","author":[{"given":"Yanni","family":"Fan","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Corporation , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Corporation , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Omidakhsh","sequence":"additional","affiliation":[{"name":"Bohn Epidemiology , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda L","family":"Bohn","sequence":"additional","affiliation":[{"name":"Bohn Epidemiology , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Thompson","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Corporation , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly G","family":"Brodovicz","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Corporation , Ridgefield, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-9784","authenticated-orcid":false,"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Diseases Center, Washington University School of Medicine in St Louis , St Louis, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"9853","key":"2023060108045078300_CIT0001","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380(","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"2023060108045078300_CIT0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2020.18936","article-title":"Management of Crohn disease: a review","volume":"325(","author":"Cushing","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"2023060108045078300_CIT0003","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113(","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2023060108045078300_CIT0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00054725-200002000-00002","article-title":"A simple classification of Crohn\u2019s disease: report of the working party for the World Congresses of Gastroenterology, Vienna 1998","volume":"6(","author":"Gasche","year":"2000","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2023060108045078300_CIT0005","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn\u2019s disease complicated by strictures: a systematic review","volume":"62(","author":"Rieder","year":"2013","journal-title":"Gut"},{"issue":"4","key":"2023060108045078300_CIT0006","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort","volume":"139(","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"2023060108045078300_CIT0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MIB.0000000000000988","article-title":"A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn\u2019s disease","volume":"23(","author":"Bettenworth","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2023060108045078300_CIT0008","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn disease: epidemiology, diagnosis, and management","volume":"92(","author":"Feuerstein","year":"2017","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"2023060108045078300_CIT0009","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/ibd\/izx108","article-title":"The management of intestinal penetrating Crohn\u2019s disease","volume":"24(","author":"Hirten","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2023060108045078300_CIT0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MIB.0000000000000977","article-title":"The cost of Crohn\u2019s disease: varied health care expenditure patterns across distinct disease trajectories","volume":"23(","author":"Rao","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2023060108045078300_CIT0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","article-title":"Clinical course and costs of care for Crohn\u2019s disease: Markov model analysis of a population-based cohort","volume":"117(","author":"Silverstein","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"2023060108045078300_CIT0012","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ibd\/izab071","article-title":"The development and initial findings of a study of a prospective adult research cohort with inflammatory bowel disease (SPARC IBD)","volume":"28(","author":"Raffals","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2023060108045078300_CIT0013","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55(","author":"Satsangi","year":"2006","journal-title":"Gut"},{"issue":"5","key":"2023060108045078300_CIT0014","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.cgh.2017.10.019","article-title":"Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review","volume":"16(","author":"de Jong","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2023060108045078300_CIT0015","doi-asserted-by":"crossref","first-page":"otab046","DOI":"10.1093\/crocol\/otab046","article-title":"Prevalence and factors associated with fecal urgency among patients with ulcerative colitis and Crohn\u2019s disease in the study of a prospective adult research cohort with inflammatory bowel disease","volume":"3(","author":"Dawwas","year":"2021","journal-title":"Crohns Colitis 360"},{"issue":"4","key":"2023060108045078300_CIT0016","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study","volume":"13(","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2023060108045078300_CIT0017","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","article-title":"Higher incidence of abnormal pap smears in women with inflammatory bowel disease","volume":"103(","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2023060108045078300_CIT0018","first-page":"496","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377(","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2023060108045078300_CIT0019","doi-asserted-by":"crossref","article-title":"FDA approves new treatment for moderately to severely active ulcerative colitis.","author":"U.S. Food and Drug Administration.","DOI":"10.31525\/fda2-ucm609225.htm"},{"issue":"1","key":"2023060108045078300_CIT0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2036.2002.01140.x","article-title":"The epidemiology and natural history of Crohn\u2019s disease in population-based patient cohorts from North America: a systematic review","volume":"16(","author":"Loftus","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2023060108045078300_CIT0021","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/gut.30.7.990","article-title":"Crohn\u2019s disease: risk of recurrence and reoperation in a defined population","volume":"30(","author":"Shivananda","year":"1989","journal-title":"Gut"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac162\/46205876\/izac162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/6\/914\/50463441\/izac162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/6\/914\/50463441\/izac162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:09:39Z","timestamp":1685592579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/6\/914\/6650080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac162","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,7,26]]}}}